Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study

Article (PDF Available)inThe Lancet Neurology 11(12) · November 2012with66 Reads
DOI: 10.1016/S1474-4422(12)70228-4 · Source: PubMed
BACKGROUND: We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease. METHODS: Between January and August, 2010, 18-26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ(1-42), total tau and phospho-tau(181) concentrations, and plasma Aβ(1-42) concentrations and Aβ(1-42):Aβ(1-40) ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests. FINDINGS: 44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ɛ4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ(1-42) concentrations (p=0·008) and plasma Aβ(1-42) concentrations (p=0·01) than non-carriers. INTERPRETATION: Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ(1-42) overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease. FUNDING: Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona.

Full-text (PDF)

Available from: Carlos Velez-Pardo, Jan 20, 2016
    • "Should a drug Q5 demonstrate cognitive benefit it will be possible to analyze which biomarkers best predicted therapeutic efficacy, findings of particular benefit for future AD trials. The need for predictive biomarkers is especially important in slowly progressive disorders like AD, without which prevention trials will necessarily be large, long, and expensive [54] . The inclusion of multiple biomarkers will allow for the analysis of multiple potential responses to therapies and also better reflect the array of biomarker used to predict progression from the observational study. "
    [Show abstract] [Hide abstract] ABSTRACT: Introduction: The Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU) is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's disease in autosomal dominant Alzheimer's disease (ADAD) families. With completion of enrollment of the first two drug arms, the DIAN-TU now plans to add new drugs to the platform, designated as the Next Generation (NexGen) prevention trial. Methods: In collaboration with ADAD families, philanthropic organizations, academic leaders, the DIAN-TU Pharma Consortium, the National Institutes of Health, and regulatory colleagues, the DIAN-TU developed innovative clinical study designs for the DIAN-TU NexGen prevention trial. Results: Our expanded trial toolbox consists of a disease progression model for ADAD, primary end point DIAN-TU cognitive performance composite, biomarker development, self-administered cognitive assessments, adaptive dose adjustments, and blinded data collection through the last participant completion. Conclusion: These steps represent elements to improve efficacy of the adaptive platform trial and a continued effort to optimize prevention and treatment trials in ADAD.
    Article · Aug 2016
    • "Interestingly, an increase in neuronal activity is observed at early stages of pathology in various forms, such as in amyloid mouse models that exhibit increased susceptibility to seizures (Del Vecchio et al., 2004; Minkeviciene et al., 2009 ) and hyperexcitability of neuronal networks (Jolas et al., 2002; Palop et al., 2007; Verret et al., 2012 ). This increase in activity has also been documented in individuals with mild cognitive impairment (MCI) (Dickerson et al., 2005), APOE ε4-positive individuals (Bookheimer et al., 2000), and even in teenagers and young adults carrying an autosomal-dominant AD gene (Reiman et al., 2012). Furthermore, this paradoxical increase in activity has been postulated to precipitate the eventual decline in synaptic and cognitive function. "
    [Show abstract] [Hide abstract] ABSTRACT: Deficits in synaptic structure and function are likely to underlie cognitive impairments in Alzheimer’s disease (AD). While synaptic deficits are commonly found in animal models of amyloidosis, it is unclear how amyloid pathology may impair synaptic function. In some amyloid mouse models of AD, however, synaptic deficits are preceded by hyperexcitability of glutamate synapses. In the amyloid transgenic mouse model TgCRND8, we therefore investigated whether early enhancement of glutamatergic transmission was responsible for development of later synaptic deficits. Hippocampi from 1-month-old TgCRND8 mice revealed increased basal transmission and plasticity of glutamate synapses that was related to increased levels of tumor necrosis factor α (TNFα). Treating these 1-month-old mice for 4 weeks with the TNFα inhibitor XPro1595 prevented synaptic deficits otherwise apparent at age 6 months. In this mouse model at least, reversing the hyperexcitability of glutamate synapses via TNFα blockade before the onset of amyloid plaque formation prevented later synaptic deficits.
    Full-text · Article · Jul 2016
    • "This is particularly important, considering the need to better understand under which circumstances this polyphenol could exert beneficial effects to brain health and plasticity. In this regard, Torres et al. [85] have demonstrated that dietary supplementation with RSV leads to increased cell proliferation in the DG, as determined by the number of Ki-67 + cells, as well as to an increase in the expression of presenilin 1, a regulator of AHN [86] and also involved in AD pathogenesis [87, 88] (reviewed in [89]). Also of interest to hippocampal plasticity and AHN, the authors found that dietary supplementation with RSV was associated with increased expression of the transcriptional repressor Hes 1, involved in stem cell maintenance through the Notch homolog 1 (NOTCH1) signaling pathway. "
    [Show abstract] [Hide abstract] ABSTRACT: The search for molecules capable of restoring altered hippocampal plasticity in psychiatric and neurological conditions is one of the most important tasks of modern neuroscience. It is well established that neural plasticity, such as the ability of the postnatal hippocampus to continuously generate newly functional neurons throughout life, a process called adult hippocampal neurogenesis (AHN), can be modulated not only by pharmacological agents, physical exercise, and environmental enrichment, but also by “nutraceutical” agents. In this review we focus on resveratrol, a phenol and phytoalexin found in the skin of grapes and red berries, as well as in nuts. Resveratrol has been reported to have antioxidant and antitumor properties, but its effects as a neural plasticity inducer are still debated. The current review examines recent evidence implicating resveratrol in regulating hippocampal neural plasticity and in mitigating the effects of various disorders and diseases on this important brain structure. Overall, findings show that resveratrol can improve cognition and mood and enhance hippocampal plasticity and AHN; however, some studies report opposite effects, with resveratrol inhibiting aspects of AHN. Therefore, further investigation is needed to resolve these controversies before resveratrol can be established as a safe coadjuvant in preventing and treating neuropsychiatric conditions.
    Full-text · Article · May 2016
Show more